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ABSTRACT  
 
A biodegradable device for controlled release of toremifene citrate was studied based upon 
ε-caprolactone and DL-lactide copolymers (P(CL/DL-LA)) and silica xerogel. The effect of 
copolymer composition, molecular weight of a copolymer, and drug loading on the release rate of 
toremifene citrate were investigated and thus it was possible to adjust the release period from 3 
months to 1 year. The applicability of the P(CL/DL-LA) copolymers for matrix type controlled 
release devices was further studied by characterizing the interactions between copolymers and 
model compounds, theophylline, propranolol hydrochloride and lidocaine by differential scanning 
calorimetry (DSC) and molecular modelling. The hydrophilicity of the copolymers as well as the 
level of average molecular weight was modified using different co-initiators i.e. glycerol and 
polyethylene glycols. Hydrolytic degradation of the copolymers was recorded and the comparison 
between degradation and release profiles was obtained. The results clearly demonstrated that the 
desired release rates of these model compounds could be tailored by varying the compound 
loading, by modifying the hydrophilicity of the matrix copolymer from matrices with low lactide 
content and by choosing the appropriate comonomer ratio between ε-caprolactone and DL-lactide. 
Two different composite materials for bone replacement were studied and their properties 
evaluated in vitro. The first material combined the P(CL/DL-LA) copolymer with bioactive glass 
S53P4 and the second was a composite consisting of amorphous lactic acid based poly(ester-
urethane) (PEU-BDI) with hydroxyapatite (HA) or biphasic calcium phosphate (BCP). The 
formation of a biologically active Ca-P layer on the surfaces of the composites in hydrolysis 
indicates in vitro bioactivity and it was found to be dependent on the weight fraction and granule 
size range of the bioactive glass used. PEU-BDI and its composites with 20 and 40 vol.% 
bioceramic filler, were characterized prior to their use as biocompatible and bioabsorbable 
artificial bone materials. The rigidity of the materials was increased with fillers, due to good 
compatibility with the matrix. Processing by melt blending and sterilization by gamma-irradiation 
caused some chemical degradation, i.e. loss of molecular weight, but did not affect dynamic 
mechanical properties. The storage modulus values of all the composite materials remained within 
ranges that were mechanically compatible with bone over the whole five weeks of hydrolysis. The 
correlation of in vitro and in vivo bioactivity of the composites needs to be established, but based 
on the in vitro evaluation, the glass composites have the potential for a variety of applications as 
implant materials in orthopaedics and dentistry and the PEU-BDI composites have potential for 
application as fracture fixation materials. 
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NOMENCLATURE 
  
 
BCP   biphasic calcium phosphate 
BDI   1,4-butane diisocyanate 
Ca-P   calcium phosphates 
CL   ε-caprolactone 
DMA   dynamic mechanical analysis 
DMTA  dynamic mechanical thermal analysis 
DSC   differential scanning calorimetry 
HA   hydroxyapatite 
HMW   high molecular weight 
LMW   lower molecular weight 
PCL   poly(ε-caprolactone) 
P(CL/DL-LA)  poly(ε-caprolactone/DL-lactide) 
P(CL80/LA20) poly(ε-caprolactone/DL-lactide), comonomer ratio in weight per cents 
PEG   poly(ethylene glycol) 
PEU-BDI  poly(ester-urethane) linked with 1,4-butanediisocyanate 
P(DL-LA)  poly(DL-lactide) 
PLA   poly(lactide) 
P(L-LA)  poly(L-lactide) 
SBF   simulated body fluid 
SEC   size exclusion chromatography 
SEM   scanning electron microscopy 
TCP   tricalciumphosphate 
 
 
SYMBOLS 
 
E'    storage modulus (Pa) 
E''   loss modulus (Pa) 
∆Εtot   energy of mixing (kcal mol-1) 
EAA, EBB, EAB  interaction energies between chain segments A and B (kcal mol-1) 
M n   number average molecular weight (g mol-1) 
M w   weight average molecular weight (g mol-1) 
MWD   molecular weight distribution 
Tg   glass transition temperature (°C) 
Tm   melting temperature (°C) 
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1 INTRODUCTION 
 
1.1 General background 
 
In the last few decades interest in biodegradable polymer materials has been steadily increasing 
and these polymers currently have two major application areas; biomedical polymers and mass-
produced applications such as packaging (Amass et al. 1998, Ikada and Tsuji, 2000). 
Bioresorbable polymers degrade in the physiological environment and the by-products are 
eliminated or completely bioabsorbed. In comparison, according to the strict definition, 
biodegradable polymers require enzymes of microorganisms for hydrolytic or oxidative 
degradation. Generally, a polymer that loses its weight over time in the living body is called an 
absorbable, resorbable, or bioabsorbable, as well as a biodegradable polymer. This terminology 
applies regardless of its degradation mode, in other words for both enzymatic and non-enzymatic 
hydrolysis. Biodegradable polymers can be classified on the basis of their origin, either naturally 
occurring or synthetic. Among synthetic resorbable polymers for implants, polyhydroxyacids 
occupy the main position. These are mainly poly(L-lactide), poly(glycolide) and copolymers 
based on L-lactide, L/DL-lactide, DL-lactide, glycolide, trimethyl carbonate and ε-caprolactone 
(Gogolewski, 2000). The largest and most enduring use of biodegradable polymers is for suturing 
(Ikada and Tsuji, 2000). Potentially, devices made from bioresorbable polymers can overcome 
problems associated with metal implants, such as stress protection, potential for corrosion, wear 
and debris formation, as well as the necessity of implant removal (Gogolewski, 2000). Resorbable 
polymers have proven to be good materials for a range of devices in trauma surgery. 
Many types of surgically implantable devices that only function for a relatively short time 
in vivo can be made from biodegradable polymers. These devices are eliminated from the body by 
hydrolytic degradation and subsequent metabolism after serving their intended purpose. The 
general criteria for selecting a polymer for use as a surgical biomaterial is to match the mechanical 
properties and time of degradation to the needs of the application. A further advantage of 
bioabsorbable polymers over nondegradable materials relates to the control over the rate at which 
mechanical properties deteriorate in vivo. Thus, fracture fixation plates, which gradually lose 
stiffness, are postulated to provide a superior result compared to steel plates, which ultimately 
weaken bone due to constant stress shielding (Barrows, 1991). Bioabsorbable devices represent 
the state of the art in managing orthopaedic problems and the use of implants in fracture fixation, 
drug delivery or ligament repair will become even more common in the next century of 
orthopaedic care (An et al., 2000). Biodegradable polymers in drug delivery technology require 
no follow-up surgical removal once the drug supply has been depleted. They have mainly been 
studied in injectable microsphere formulations, although implantable rods and pellets are also 
being investigated (Lewis, 1990). Resorbable materials are particularly promising as short-term or 
transient implants, namely bone plates, screws, pins, rods, ligaments, tendons, bone replacement, 
vascular grafts, and artificial skin (Ramakrishna et al., 2001).  
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1.2 Biomaterials and prerequisites for biomedical applications 
 
A biomaterial is a non-viable material used in a medical device that is intended to interact with 
biological systems (Williams, 1990). The biomaterials spectrum includes metals and alloys, 
polymers, plastics, elastomers and fibres, ceramics and glasses, composites and natural materials 
and their synthetic analogues. Due to the close contact of biomaterials with biological systems, the 
interaction and biocompatibility of synthetic polymers are of prime concern. The properties 
required of polymeric biomaterials are similar to other biomaterials, i.e. biocompatibility, 
sterilizability, adequate mechanical and physical properties, and manufacturability. 
Biocompatibility means the acceptance of an implant by surrounding tissues and by the body as a 
whole. The implant should be compatible with tissues in terms of mechanical, chemical, surface, 
and pharmacological properties. Biocompatibility is defined as the ability of a material to perform 
with an appropriate host response in a specific application (Williams, 1987), where host response 
is the reaction of a living system to the presence of a material. Body fluids can act as a solvent for 
impurities entrapped within a polymer matrix. On the other hand, compounds issued from 
polymerisation and processing stages, namely monomers, oligomers, initiators, solvents, etc., can 
generate particular morphological characteristics such as crystallinity or porosity, and cause 
toxicity or undesired physical aging due to slow release or slow uptake of low molecular weight 
compounds according to phase partition (Vert, 2000). 
Ceramics, glasses and glass-ceramics used in biological applications are referred to as 
bioceramics. They can be divided into relatively inert, bioactive or surface reactive, and 
biodegradable or resorbable types (Hench and Wilson, 1993). Bioactive materials can bond to 
bone chemically and are defined as materials that elicit a specific biological response at the 
interface of the materials resulting in the formation of a bond between the tissues and material 
(Hench and Andersson, 1993). Since the discovery of Bioglass® by Hench and co-workers (1971) 
the bioactivity of a variety of glass compositions has been well established (Kokubo et al., 1990a, 
Andersson et al., 1990, Brink et al., 1997). Resorbable ceramics degrade on implantation in the 
host and the rate of degradation varies from material to material (Bajpai and Billotte, 1995). 
Almost all bioresorbable ceramics are variations of calcium phosphate. Several types of calcium 
phosphate (Ca-P) materials are used in bone repair and augmentation (LeGeros and LeGeros, 
1996) and it is known that Ca/P ratios within the range 1.50 to 1.67 promote bone ingrowth (Klein 
et al., 1983). Because most structural living tissues (bone, ligament, connective tissue etc.) are 
macromolecular composites, synthetic polymeric composites are an attractive group of materials 
for the development of new, tailor-made biomaterials for replacing, supporting, augmentation or 
fixation of living tissues (Törmälä and Pohjonen, 1997). The original concept of bioceramic 
reinforced polymer composites, i.e., ceramic materials conferring stiffness and biological activity 
to the composite material while the viscoelastic polymer compensates for the brittle ceramics, was 
introduced by Bonfield and co-workers in early 1980´s (Bonfield et al., 1981). The properties of 
the composite material depend on the shape and size of the filler, the volume fraction and the 
integrity of the interface between the constituents.  
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The two major routes in obtaining an acceptably sterile product are aseptic manufacturing 
and terminal sterilisation. For economical and practical reasons, the latter strategy is considered a 
more realistic approach to achieve sterile biomedical devices. Commonly used sterilisation 
techniques are dry heat, autoclaving, ethylene oxide gas, and radiation (Lee et al., 1995). Low-
temperature radio-frequency glow discharge plasma treatment has also been introduced as a 
sterilization method for polyester devices (Holy et al., 2001). Conventional methods such as dry 
or moist heat sterilization often initiate degradation and hydrolysis of the devices used, and 
ethylene oxide, due to residual amounts, often causes toxicological problems. Thus, irradiation 
sterilization of pharmaceutical preparations has become popular in recent years. Radiation 
sterilization causes alterations in the molecular structures of the polymers, which appear as 
changes in the chemical or physical properties (Sintzel et al., 1997). Sterilizability should thus be 
considered early in the development of new biomaterial devices. 
 
 
1.3 Synthetic bioresorbable polyesters  
 
Biodegradation can be accomplished by synthesizing polymers that have hydrolytically unstable 
linkages in the backbone. The most common chemical functional groups of this kind are esters, 
anhydrides, orthoesters, and amides. Depending on the chemical structure of the polymer 
backbone, degradation can occur by either surface or bulk erosion. Surface erosion occurs when 
the rate of erosion exceeds the rate of water penetration into the bulk of the polymer. This type of 
degradation can be obtained in poly(anhydrides) and poly(ortho esters) (Domb et al., 1997, Heller 
et al., 2000). The hydrolysis of bulk degrading bioresorbable polymers usually proceeds by loss of 
molecular weight at first, followed by loss of mass in the second stage. Generally, hydrolysis 
(including enzyme-mediated hydrolysis) is the most probable degradation mechanism for hetero-
chain polymers in vivo (Williams, 1994). The degradation of poly(ε-caprolactone) (PCL) and 
related polyesters such as poly(lactide) (PLA) and its copolymers first involves non-enzymatic 
hydrolysis of ester linkages, autocatalyzed by the generation of carboxylic acid end groups, 
followed by the loss of mass (Ali et al., 1993). The role of enzymes in the degradability of 
aliphatic polyesters is under investigation (MacDonald, 1996, Gan et al., 1999, Chen et al., 2000, 
Li et al., 2001). 
The factors that affect the mechanical performance of biodegradable polymers are 
monomer selection, polymerisation and process conditions, and the presence of additives (e.g. 
fillers). These factors, in turn, influence the hydrophilicity, crystallinity, melt and glass transition 
temperatures, molecular weight, molecular weight distribution, end groups, sequence distribution 
(random versus block), and the presence of residual monomer or additives in the polymer 
(Middleton and Tipton, 2000). Furthermore, all these together then influence the rate of 
biodegradation of the polymer. 
Aliphatic polyesters can be synthesized by polycondensation from a mixture of a diol and 
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diacid, from a hydroxy acid or by ring-opening polymerisation of lactones. Polycondensation 
requires high temperatures and long reaction times to produce high molecular weight chains. In 
contrast ring-opening polymerisation can be used to prepare high molecular weight polymers in 
short periods of time under relatively mild conditions (Löfgren et al., 1995). Ring-opening 
polymerisation of lactones can be initiated by different mechanisms. When stannous octoate is 
used as a catalyst, it first reacts with compounds containing hydroxyl groups forming tin alkoxide, 
which then acts as an actual initiator in the polymerisation (Duda et al., 2000). The structure of 
the polymer depends on these alcohols used as co-initiators. Mono- and difunctional alcohols 
yield linear polymers, while alcohols with hydroxyl functionality higher than two give star- or 
comb-shaped polymers (Schindler et al., 1982, Korhonen et al., 2001). Another effective way of 
producing high molecular weight polyesters is to treat condensation polymers of lactic acid with 
chain extenders. Among chain linking agents, the extremely high reactivity of the diisocyanates 
has encouraged their use for coupling or chain extension of oligomers (Hiltunen et al., 1997).  
Lactide is the cyclic dimer of lactic acid, which exists in three stereoisomeric forms, L-
lactide, naturally occurring isomer, D-lactide and meso-lactide, which contains a L-lactyl unit and 
a D-lactyl unit in the ring. Additionally, DL-lactide is an equimolar mixture of L- and D-lactides. 
Poly(L-lactide) (P(L-LA)) exhibits high tensile strength and low elongation and consequently has 
a high modulus that makes it more applicable than the amorphous polymers for load-bearing 
applications such as orthopaedic fixation and sutures. P(L-LA) has a melting point around 170°C 
and glass transition temperature in the range of 55-60°C. Poly(DL-lactide) (P(DL-LA)) is an 
amorphous polymer (Tg 45-55°C), having a random distribution of both isomeric forms of lactic 
acid and lacking the ability to arrange into a crystalline organized structure. P(DL-LA) has a 
lower tensile strength, slightly higher elongation and substantially more rapid degradation time, 
making it more attractive for use in drug delivery system. PCL is a ductile semicrystalline 
polymer, melting in the range of 54-64°C. The glass transition temperature of 60°C can be 
increased by copolymerisation with lactide, which also enhances the biodegradation of the 
polymer. PCL has good permeability to many therapeutic drugs and has been studied for long-
term contraceptive delivery (Pitt, 1990). 
The in vivo elimination time of bioresorbable polymers is determined by the nature of the 
polymer chemical linkage, the solubility of the degradation products, the size, shape and density 
of the device, the drug and additive content, the molecular weight of the polymer, and the 
implantation site (Domb et al., 1998). Semicrystalline P(L-LA) has a degradation time in the 
order of 3 to 5 years, whereas P(DL-LA) degrades in 12 to 16 months (Pitt et al., 1981, Bergsma 
et al., 1995). Polyhydroxyacids degrade to monomeric acids and subsequently to carbon dioxide 
and water. These are removed from the body via respiratory routes and the kidneys (the Krebs 
cycle) (Grijpma et al., 1991, Gogolewski, 2000). Copolymers of ε-caprolactone with L- or DL-
lactide have been reported to induce only mild foreign-body reactions (den Dunnen et al., 1997, 
Tomihata et al., 1998), and aliphatic polyesters in general are considered biocompatible (Vert et 
al., 1992). 
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1.4 Biomedical applications 
 
Controlled release delivery systems 
Controlled release dosage forms enhance the safety, efficacy and reliability of drug therapy, 
particularly for drug substances with a narrow therapeutic index (Thombre and Cardinal, 1988). 
They regulate the drug release rate to control the drug action, and reduce the frequency of drug 
administration to encourage the patients to comply with dosing instructions. Conventional dosage 
forms often lead to wide swings in serum-drug concentrations (Figure 1). Most of the drug content 
is released soon after administration, causing drug levels in the body to rise rapidly, peak, and 
then decline sharply. Since each drug has a therapeutic range above which it is toxic and below 
which it is ineffective, oscillating drug levels may cause alternating periods of ineffectiveness and 
toxicity (Edgren et al., 1993, Langer, 1995). 
 
 
Figure 1. Controlled delivery versus immediate release delivery with repeated administration. 
 
 Controlled delivery devices are generally diffusion-based release systems applicable to the 
release of drugs intended for the systemic circulation or for a localized site (Griffith, 2000). 
Diffusion is defined as a process of mass transfer of individual molecules of a substance, brought 
about by random molecular motion and associated with a concentration gradient (Martin, 1993). 
In monolithic devices, the drug is uniformly mixed with the polymeric matrix and is present either 
in dissolved or dispersed form (Baker, 1987). Release follows Fickian kinetics from devices 
where the drug is dissolved. When the drug is dispersed in the matrix, it is released according to 
square root of time kinetics until the concentration in the matrix falls below the saturation value. 
The range of formulation variables available to control the rate of drug release from controlled-
release devices is broad. The desired drug release profile in bulk degrading systems can be 
obtained by adjusting the molecular weight of the polymer, comonomer composition, polymer 
crystallinity, shape and preparation method of the device, interaction between polymer and drug, 
and drug loading (Buntner et al., 1996, Vandamme and Mukendi, 1996, Ye and Chien, 1996, 
Miyajima et al., 1997 & 1998, Lemmouchi et al., 1998).  
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Bioresorbable composite materials for tissue engineering 
Tissue engineering can be defined as the application of scientific principles to the design, 
construction, modification, growth, and maintenance of living tissues. Tissue engineering can be 
divided into two broad categories: 1) in vitro construction of bioartificial tissues from cells 
isolated by enzymatic dissociation of donor tissue and 2) in vivo alteration of cell growth and 
function. The first category of applications includes artificial tissues (i.e., tissues that are 
composed of natural and synthetic substances) to be used as an alternative to organ 
transplantation. For tissue engineering in vivo, the objective is to alter the growth and function of 
cells in situ, an example being the use of implanted polymeric tubes to promote the growth and 
reconnection of damaged nerves (Berthiaume and Yarmush, 1995). Polymeric biomaterials in 
tissue engineering research are being applied in conducting, guiding, and inducing tissue 
formation as well as in blocking tissue interactions. These polymers for structural scaffolds 
require suitable physical and mechanical properties, designable biodegradability, non-toxicity, 
good biocompatibility, and the ability to interact with specific cells. Scaffolds meeting these 
requirements may be useful in regenerating damaged tissues or organs by combining scaffolds 
with living cells (Han et al. 1998). 
Figure 2 shows the integration of material and engineering properties in order to achieve a 
successful biomaterial for tissue regeneration. In addition, there are the biological and medical 
requirements that need to be satisfied in the appropriate design of a new material (Seal et al., 
2001). 
 
 
 
Figure 2.  Illustration of how some material, biological, medical and engineering properties must be 
integrated to achieve successful biomaterials for tissue regeneration (Seal et al., 2001). 
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The idea of using polymers as binders for particulate bioceramics to produce composites 
with improved handling and retention characteristics and to overcome the problem of brittleness 
associated with ceramic bone repair implants has been evaluated as an attractive approach. The 
critical properties of a composite implant material to be used in load-bearing areas include the 
degree of strength retention over time, and the structural and mechanical equivalence to bone. 
However, the main requirements for a bone-filling material are its degradation rate, it should 
degrade at about the same rate as the new hard tissue is formed, and also its handling properties, 
which means that it should be easy to place tightly within the gap in the bone (Ural et al., 2000).  
 
 
1.5 Scope of the study 
 
The polymerisation of lactic acid based biodegradable polymers and copolymers of lactic acid or 
lactide with ε-caprolactone has been extensively studied over the last decade in the laboratory at 
Helsinki University of Technology (Hiltunen, 1997, Kylmä, 2001, Hiljanen, 2001). Bioresorbable 
polymers have been synthesized by ring-opening polymerisation or polycondensation followed by 
chain linking. As the synthesis of these polymers, characterization of mechanical properties and 
hydrolytic degradation was under way, it also became of interest to study the application areas of 
these bioresorbable polymers, especially in biomedical field.  
This thesis discusses the research reported in six appended publications (I-VI). In the first 
four publications (I-IV) copolymers of DL-lactide and ε-caprolactone were modified and 
characterized in vitro for controlled drug delivery applications. Bioactive composite materials for 
bone replacement were characterized in Publications V and VI. Figure 3 shows the structure of 
poly(ε-caprolactone/DL-lactide) P(CL/DL-LA) used in Publications I-V and Figure 4 shows the 
structure of lactic acid based poly(ester-urethane) (PEU-BDI) used in study VI.  
 
Figure 3.  Structure of the bioresorbable copolymer (P(CL/DL-LA). 
 
Biodegradable devices for the controlled release of toremifene citrate were developed in 
Publications I and II. Toremifene citrate is an antiestrogenic compound that exerts its antitumor 
action through inhibition of the estrogen-mediated growth stimulus (Valavaara, 1990). 
Antiestrogens have been used in the systemic treatment of hormone-dependent breast cancer 
(Kallio et al., 1986) and thus local hormone therapy after breast cancer surgery could provide 
targeted and long-lasting disease control. The effects of comonomer ratio, average molecular 
weight, drug load, and incorporation of toremifene citrate into silica xerogel on the release were 
studied. The release properties of P(CL/DL-LA) copolymers were further characterized in 
x y
n
CH2 CH2 CH2 CH2 CH2 C
O
O CH C
O
O CH C
O
CH3CH3
O
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Publications III and IV. The release of two model compounds, theophylline and propranolol 
hydrochloride, at different loadings, was carried out as the hydrophilicity of the copolymers was 
modified using different co-initiators in Publication III. Release properties of the copolymer 
matrices with low caprolactone content were characterized in Publication IV, where molecular 
modelling was additionally applied to provide insight into the interactions between the polymer 
matrix and the active component. 
 
Figure 4.  Structure of lactic acid based poly(ester-urethane). 
 
 Ductile P(CL/DL-LA) copolymer with minor lactide content with bioactive glass for the 
filling of bone defects and guided tissue regeneration was studied in Publication V. Different 
amounts of bioactive glass were incorporated in the matrix in order to obtain slower (40 wt.% 
glass) or accelerated bioactivity (60 or 70 wt.%), i.e., slower or faster formation of a silica gel 
layer on the surface of the composite in dissolution. Two ranges of granule size were chosen for 
the experiment in order to change the area/volume ratio of the bioactive glass in the composite. 
The molecular weight and the melting temperature of the copolymer matrix were adjusted to 
enable the application of the composite material by injection below 50°C. The preparation, 
morphology, dynamic mechanical properties, and in vitro hydrolysis of the composite material 
were reported. 
Highly crystalline polymers, such as P(L-LA), can disintegrate into crystalline particles, 
which can cause late foreign body reactions (Bergsma et al., 1995). A solution to this is to use 
amorphous polymers, which degrade without generation of crystalline remnants. Polyurethanes, 
on the other hand, have been used for a variety of biomedical applications due to their excellent 
physical properties and relatively good blood compatibility, and because they can be readily 
tailored either by changing the components used or by changing the length of prepolymer. In this 
study, lactic acid prepolymer was linked with 1,4-butane diisocyanate (BDI) and, due to the 
relatively long poly(lactic acid) prepolymer chains, the amount of urethane units in PEU-BDI was 
below 2 wt.%. Therefore, the physical properties of PEU-BDI are similar to amorphous P(DL-
LA), but additional improvements in compatibility and adhesion at the interface of fillers and 
matrix have been obtained in association with the urethane groups (Hiljanen-Vainio et al., 1997, 
Kylmä et al. 2000 & 2001b). A composite material consisting of amorphous PEU-BDI reinforced 
with bioceramic fillers was developed and characterized in vitro for use as a bone replacement 
material in Publication VI.  
O C NH
O
(CH2)4 NH C O O
O
n
Poly(ester-urethane), PEU-BDI
where                        is lactic acid prepolymer (Mw ~30 000 g/mol)
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2 EXPERIMENTAL 
 
2.1 Materials 
 
ε-Caprolactone (Fluka or Solvay Interox Ltd.) was dried over molecular sieves. DL-lactide 
(Purac) was recrystallized from toluene. Purified lactide was dried at 40°C for 24 h under reduced 
pressure before polymerisation. L-Lactic acid (88% L-lactic acid in water, 99% optically pure; 
ADM: Archer Daniels Midland Co.) was purified by distillation under vacuum. Sn(II) octoate 
(Sigma Aldrich Chemical Co.), glycerol (Rhône-Poulenc or Prolabo), 1,4-butanediol (Acros 
Organics) and 1,4-Butane diisocyanate (Aldrich) were used as received. Polyethylene glycol 
(PEG) 1000 and 4000 (Fluka) were dried under reduced pressure for 24 hours before 
polymerisations. Theophylline (Fluka), propranolol hydrochloride (Fluka), lidocaine (Sigma-
Aldrich Chemie Gmbh), 0.85w/v saline (Sigma Diagnostics) and buffer solutions pH 7.0 
(Reagecon) were used as received. Chemical structures of the drugs used as model compounds are 
shown in Figure 5 and some of their characteristics are listed in Table 1 (Publications III and IV).  
 
N
N
NH
N
O
O
H3C
CH3
Theophylline Propranolol hydrochloride
NH2
CH3
CH3
OH
O
Cl
CH3
CH3
NH C CH2
O
N
CH2CH3
CH2CH3
Lidocaine  
Figure 5.  Structure of the used model compounds. 
 
Table 1.  Characteristics of the model compounds used in Publications III and IV. 
 
Model compound 
 
 
Molecular 
weight 
(g mol-1) 
Melting 
temperature 
(°C) 
Maximum absorption 
wavelength 
(nm) 
Theophylline 180 274-275 275 
Propranolol 
hydrochloride 259 163-164 214 
Lidocaine  234 66-69 262 
 
 
 Bioactive glass S53P4 (Abmin Technologies) consisted of 53 wt.% SiO2, 23 wt.% Na2O, 
20 wt.% CaO, and 4 wt.% P2O5 (Publication V). The granule size ranges were < 45 µm and 90  
315 µm. The density of the bioactive glass was 2.66 g cm-3. Two bioceramic fillers were used, 
synthetic hydroxyapatite (HA) (P218 grade, Plasma Biotal Ltd) and biphasic calcium phosphate 
(BCP) prepared from Merck calcium phosphate (tricalciumphosphate, Merck GmbH) 
(Publication VI). Tricalciumphosphate (TCP) was calcinated at 900°C for 2 hours, which 
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transformed it to a crystalline biphasic calcium phosphate containing approximately 70% β-TCP 
and 30% HA, the Ca/P ratio was 1.56 (Bleach et al., 2002). The mean particle diameters of the 
fillers were d0.5= 2.99 µm for HA and d0.5= 3.44 µm for BCP. The specific surface areas were 
substantially different at 16.3 and 3.15 m2 g-1 respectively; the densities of the fillers were 
3.16 g cm-3 (HA) and 3.12 g cm-3 (BCP). 
The silica xerogel used was prepared using the sol gel method described in detail in 
Publications I and II. Toremifene citrate (Orion Corporation) was used as a model drug, which 
was either adsorbed on the silica surface (Publication I) or impregnated during the sol-gel process 
(Publication II). 
 
 
2.2 Polymerisation procedures 
 
The ring-opening polymerisation of ε-caprolactone and DL-lactide was carried out in bulk under 
an argon atmosphere with Sn(II) octoate as an initiator. Glycerol was used as a co-initiator in most 
polymerisations (0.05-0.5 mol%) but additionally polyethylene glycols were used in Publication 
III as co-initiators (0.1 and 0.5 mol%). Typically (Publications I and II), a batch of 300 grams of 
monomers, initiator and co-initiator in a glass polymerisation flask with magnetic stirrer was 
immersed in an oil bath. The polymerisation time was 54 hours at 120°C or 24 hours at 140°C. 
The polymerisation of ε-caprolactone and DL-lactide in Publications III, IV and V were also 
carried out in bulk. Typically, 1000 grams of monomers, Sn(II) octoate as an initiator and co-
initiator were charged into a 2.5-litre batch reactor (Design Integrated Technologies) designed for 
the agitation of viscous materials. The polymerisations were carried out at 160°C for 4.5 to 8 
hours under a nitrogen atmosphere. The copolymers were stored in dry conditions and used 
without further purification. 
The hydroxyl-terminated prepolymer for poly(ester-urethane) synthesis was condensation 
polymerised in a rotation evaporator using 1,4-butanediol and Sn(II) octoate as a catalyst to 
produce hydroxyl-terminated oligomer. The chain linking polymerisation of the prepolymer was 
then carried out in a batch mixer (Brabender W50EH) with the use of 1,4-butane diisocyanate 
(BDI) as a chain extender. The synthesis of poly(ester-urethane) is described in detail in 
Publication VI. The polymer was purified by precipitating it out from a dichloromethane solution 
with ethanol. Composite and PEU-BDI samples in study VI were sterilized by γ-irradiation, with a 
nominal dose of 2.9 Mrad (Isotron plc).  
 
 
2.3 Preparation of specimens 
 
P(CL/DL-LA) copolymers were blended with toremifene citrate, silica xerogel, or bioactive glass 
in a batch mixer (Brabender W50EH) at 100°C for 5 minutes at 60-75 rpm (I, II, V). HA and BCP 
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fillers were blended with PEU-BDI in a Brabender mixer at 130°C for 5 min at 60 rpm (VI). 
Model compounds (theophylline, lidocaine, and propranolol hydrochloride) were mixed into 
P(CL/DL-LA) in a co-rotating twin-screw midi extruder (DMS, capacity 16 cm3, screw length 
150 mm) (III and IV). In the case of blend devices, the model compound was mixed together with 
the blend components in one batch. The midi extruder had a back-flow channel and was operated 
batch-wise. The screw speed was 75 rpm and the mixing time was three minutes at 100°C.  
Test specimens were prepared either by compression moulding or injection-moulding. The 
disc specimens (diameter 10 mm, thickness 2 mm) were compression moulded (Fontijne TP400) 
(II and V) and square shaped test specimens (10x10x3 mm3 (I) or 10x10x0.6 mm3 (II)) were 
prepared by punching them out from compression-moulded plates with an Elastocon EP 02 
puncher. Rectangular shaped devices (10x4 mm2, thickness 1.8 mm) and specimens for dynamic 
mechanical thermal analysis (DMTA) measurement were prepared using a mini injection-
moulding machine attached to the midi extruder (DMS) (III, IV and VI).  
 
 
2.4 Hydrolysis tests 
 
Hydrolysis tests were carried out in buffer solution (pH 7.0 at 20°C) (III, IV), simulated body 
fluid (SBF K9, pH 7.25 at 37°C, Kokubo et al., 1990b) (I, II, V), or 0.85w/v saline solution (VI). 
In all studies, a number of test specimens were immersed individually in the dissolution medium 
(10-25 mL) and in release tests the medium was changed to maintain sink conditions. The test 
tubes were placed in an incubator or mixed air bath maintained at 34°C (I and II) or 37°C (III-VI). 
The specimens were recovered at predetermined times and weighed. Specimens were then 
vacuum-dried for six days at room temperature, weighed again and stored in a desiccator for 
further characterization; size exclusion chromatography (SEC), differential scanning calorimeter 
(DSC) analysis or dynamic mechanical thermal analysis (DMTA) (IV-VI). The amount of 
released model compound (I-IV) was determined from the solution medium by an UV-visible 
spectrophotometer (Hewlett Packard 845/A or Unicam UV/VIS spectrometer) at the maximum 
absorbance of toremifene citrate (278 nm), theophylline (275 nm), propranolol hydrochloride (214 
nm) and lidocaine (262 nm). Degradation of the silica xerogel was determined by measuring 
dissolved Si(OH)4 spectrophotometrically as molybdenum blue complex at 820 nm (I and II). 
 
 
2.5 Characterization 
 
Molecular weights were determined by room temperature SEC (Waters System Interface module, 
Waters 510 HPLC Pump, Waters 410 Differential Refractometer, Waters 700 Satellite Wisp, and 
four linear PL gel columns: 104 Å, 105 Å, 103 Å and 100 Å connected in series). Chloroform was 
used as solvent and eluent for polymers. The samples were filtered through a 0.5 µm Millex SR 
 18 
filter. The injected volume was 200 µL and the flow rate was 1 mL min-1. Monodisperse 
polystyrene standards were used for primary calibration. 
The structures of the copolymers in Publications I and II were determined with a Varian 
Unity 400 NMR spectrometer working at 100.577 MHz for 13C and at 399.96 MHz for 1H. The 
measurement temperatures were 45°C for 13C NMR and 18°C for 1H NMR. Tetramethylsilane 
was used as an internal standard. The structures of copolymers in Publications III-V were 
determined with a Varian Gemini 2000, 300 MHz NMR spectrometer working at 75.452 MHz for 
13C and at 300.032 MHz for 1H. The measurements were carried out at room temperature. 
Thermal properties were measured by DSC and DMTA. The DSC measurements (Polymer 
Laboratories or Mettler) were carried out in the temperature range between -100°C and +200°C 
depending on the polymer and the heating rate was 10°C min-1 or 40°C min-1 (I-VI). Nitrogen was 
used as a sweeping gas. The samples (6-8 mg) were heated twice to ensure that their thermal 
histories were similar. Changes in crystallinity of the devices as a function of hydrolysis time 
were evaluated from the first heating scan in Publications II and III. The DMTA measurements 
were performed on a Perkin Elmer 7 Series Thermal Analysis System instrument (IV-VI). The 
measurements were carried out using the three-point bending over a temperature range of -90 to 
100°C (IV), -90 to 45°C (V) or 20 to 80°C (VI) at a heating rate of 4°C min-1 and a frequency of 
1 Hz.  
The morphology of the cryogenically fractured samples was examined by scanning 
electron microscopy (SEM) (JEOL JSM-840A, JSM-6335F or Zeiss Digital Scanning Microscope 
962). Surfaces were coated with a thin layer (10-20 nm) of platinum or gold before examination. 
(I, IV, V and VI) 
 
 
2.6 Molecular modelling 
 
For molecular modelling, the Polymer software package by Molecular Simulations Inc. was used. 
The calculations were carried out on a Silicon Graphics workstation Indigo2 Impact 10000. The 
structure of theophylline was optimised using the semiempirical AM1 method. The partial charge 
distribution (ESP charges) and the dipole moment were also calculated. ESP charges are the 
partial charges of the atoms in the molecule; optimised to reproduce the quantum chemically 
calculated electrostatic potential around the molecule. The molecular mechanics and dynamics 
simulations were performed using the Discover 97.0/4.0.0.P software by MSI16. The polymer 
consistent force field (pcff) was used in these calculations. 
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3 RESULTS AND DISCUSSION 
 
3.1 Copolymer/silica xerogel composites for controlled release of toremifene citrate 
 
The copolymers exhibit a broad range of properties depending on the type and proportions of their 
constituent monomers. PLA, PCL, and copolymers of lactide (LA) and ε-caprolactone (CL) have 
been studied as controllable dosage forms that biodegrade after drug exhaustion (Pitt et al., 1979, 
Lemmouchi and Schacht, 1997). Different comonomer ratios of the copolymers are designated 
here with the weight ratios of comonomers in the feed, e.g. P(CL80/LA20) consists of 80 wt.% of 
ε-caprolactone and 20 wt.% DL-lactide. The goal of the study was to develop a controlled release 
formulation of toremifene citrate using biodegradable delivery systems based upon ε-caprolactone 
and DL-lactide copolymers and silica xerogel (Publications I and II). The effect of copolymer 
composition, molecular weight of a copolymer, and drug loading on the release rate of toremifene 
citrate were investigated. In addition, the role of hydrophilic silica xerogel in the release of the 
drug from different copolymers was examined. Toremifene citrate was either adsorbed on the 
silica surface (Publication I) or impregnated during the sol-gel process (Publication II). The 
devices studied were of an appropriate size for subcutaneous or intramuscular implantation, i.e. 
discs. 
 
 
3.1.1 Effect of copolymer composition and drug load 
 
P(CL/DL-LA) copolymers with four different comonomer ratios were polymerised and both 
copolymer matrix and copolymer/silica xerogel composite devices containing the drug were 
prepared. The copolymer devices contained 2 wt.% of the drug and composite devices contained 
20 wt.% silica xerogel, corresponding to 1.6 wt.% drug content. The results from copolymer 
matrices and silica xerogel composite devices for different comonomer ratios are shown in Figure 
6. The total release time of toremifene citrate increased from about 70 to 200 days with increasing 
weight fraction of ε-caprolactone in both types of devices. Copolymers containing larger amounts 
of DL-lactide (40-80 wt.%) were not suitable matrices to deliver toremifene citrate in a controlled 
manner because of the burst effect observed at about 80 days. At that time, the rate of release 
changed significantly and the desired steady release rates over the whole release period were not 
obtained. The onset of rapid drug release may be attributed to the hydrolytic degradation of the 
matrices. The degradation effects were not studied here but were later confirmed to be a 
significant factor in determining the release properties of high lactide content copolymers 
(Publication IV.)  
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Figure 6.  Cumulative release of toremifene citrate from a) copolymers and b) composites of these 
copolymers containing silica xerogel: P(CL80/LA20) (∆), P(CL60/LA40) (◊), 
P(CL40/LA60) (○), P(CL20/LA80) (●). Results are averages (n=3) with standard error 
bars, (Data from I). 
 
 
Results indicate that the release profiles of toremifene citrate were quite similar from both 
types of devices. The release profiles of toremifene citrate followed matrix-diffusion kinetics at 
the beginning, before a burst phase occurred. Silica xerogel delayed the beginning of the burst 
effect in the copolymer containing 20 wt.% ε-caprolactone but the desorption of the drug from the 
silica xerogel was not a significant factor in determining the rate or the profile of the release from 
any of the devices tested. Apparently, toremifene citrate was already partly released from the 
surface of silica xerogel during blending with the copolymer, and thus the effect of the silica 
xerogel on the release rate of the drug is not clear. Since P(CL80/LA20) provided the most 
uniform rate of toremifene citrate release, it was selected for drug loading studies with 2, 3, 4 and 
10 wt.% drug in the copolymer. Figure 7 shows the cumulative release profiles for different drug 
loads. Increasing the initial drug loading increased the fraction of toremifene citrate released from 
the matrix, i.e. the relative release rate was constant and the amount released was found to be 
directly proportional to the toremifene citrate load when more than 2 wt.% was used. It can be 
speculated that 2 wt.% of the drug is dissolved in the matrix and thus the release rate observed is 
faster. The deviations from linearity with 10 wt.% load may be due to toremifene citrate 
catalysing the degradation of the matrix, leading to an increased release rate.  
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Figure 7.  Effect of drug loading on the release from P(CL80/LA20) matrix, load 2 wt.% (∆), 3 wt.% 
(◊), 4 wt.% (○), and 10 wt.% (●). Results are averages (n=3) with standard error bars, 
(Data from I). 
 
 
3.1.2 Effect of the molecular weight on the release profile 
 
The results of the first study indicated that the in vitro release of toremifene citrate could be 
adjusted by selecting an appropriate polymer composition and by varying the initial drug loading. 
The next point of interest involved the effects of the molecular weight of the copolymer and 
incorporation of the drug into silica xerogel during the sol gel process, instead of the adsorption 
method. Lower and higher molecular weight P(CL80/LA20) copolymers (!w 60 000 g mol-1 
(LMW) and !w 300 000 g mol-1 (HMW)) were used in the devices. The level of the molecular 
weight was adjusted by the amount of glycerol co-initiator used in the ring-opening 
polymerisation. Copolymerisation of ε-caprolactone with 20 wt.% DL-lactide lowers the 
crystallinity compared with pure PCL, which should enhance the diffusion through the matrix. 
Also, the more hydrophilic lactide units promote the degradation of copolymer compared with 
PCL homopolymer. Matrix devices contained 2 wt.% toremifene citrate and composite devices 
contained 8.7 wt.% silica xerogel, corresponding to 2 wt.% drug content. Cumulative toremifene 
citrate releases from both types of device are shown in Figure 8.  
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Figure 8.  Release of toremifene citrate from the P(CL80/LA20) (copolymer/drug) device and the 
(copolymer /drug impregnated silica xerogel) composite devices. LMW device (○), LMW 
composite device (□), HMW device (●), HMW composite device (■), and HMW thin plate 
device (▲). Results are averages (n=3), error bars have been omitted for clarity (see Fig. 5 
in II). 
 
 
The release rate of toremifene citrate was steady for almost one year and no abrupt 
changes were observed in the release rate from LMW P(CL/LA) matrix and composite devices. 
Toremifene citrate release was clearly faster in the beginning from both matrix and composite 
devices made with LMW P(CL/LA) than from devices with HMW P(CL/LA). Similar findings 
regarding the role of the molecular weight of P(CL/LA) copolymer controlling the release rate 
have been reported by Wada et al. (1991). When the released amount (up to 70%) was plotted 
against the square root of the release time, a linear correlation was obtained (r=0.995). Thus, 
release rates determined from the slopes of the curves showed that toremifene citrate released at a 
constant rate of 4.54%/day½ from the LMW P(CL/LA)/drug matrix device according to square 
root of time kinetics. Toremifene citrate also released from the HMW P(CL/LA)/drug matrix 
devices according to square root of time kinetics (correlation r=0.948) at the rate of 3.5%/day½ 
before the abrupt change in the rate of release. The onset of faster drug release from HMW 
devices was after 160 days of hydrolysis, at which time the weight average molecular weight had 
decreased below 50 000 g mol-1. It was clear that the degradation of the copolymer affected, and 
possibly preceded, the diffusion of the drug from the device. The incorporation of drug into silica 
xerogel moderated the change of release rate from HMW P(CL/LA) devices, but did not affect the 
release before the abrupt change in the rate of release. The release rate can be further modified by 
changing the device geometry (Wada et al., 1991, Lemmouchi and Schacht, 1997), and thus it was 
confirmed that a good release profile and release duration of about three months was obtainable 
using a thin plate HMW P(CL/LA) device. 
The degradation of polyesters proceeds in two stages. The first stage involves a decrease 
in molecular weight produced by non-enzymatic, random hydrolytic scission of ester cleavage, 
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and its duration is determined by the initial molecular weight of the polymer and its chemical 
structure (Pitt et al., 1981b, Malin et al., 1996). The second degradation stage is characterised by 
mass loss and a change in the rate of chain scission. The change in the rate of chain scission was 
observable for HMW P(CL/LA) after 182 days of hydrolysis (Figure 9). At that time, the mass 
loss was 10 wt.%. No change in the rate of chain scission was observed in the studied hydrolysis 
time for the LMW P(CL/LA), although the mass loss at 326 days of hydrolysis was 25 wt.%. The 
semilog plot of the in vitro rate of hydrolytic chain scission for the polymer samples over 300 
days hydrolysis is shown in Figure 9.  
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Figure 9.  Semilog plot of the in vitro rate of hydrolytic chain scission of the P(CL80/LA20) 
copolymers LMW (□) and HMW (■). Results are averages (n=2) (II). 
 
 
The weight average molecular weight of HMW P(CL/LA) samples containing drug or 
drug impregnated silica dropped 35% in just fourteen days of hydrolysis. On the other hand, the 
weight average molecular weight of LMW P(CL/LA) hardly changed at all over the same time. In 
general, the drug or silica impregnated samples degraded slightly faster than the polymer samples 
due to the higher water absorptions. This difference in degradation rate was more noticeable in 
HMW P(CL/LA) samples. The LMW copolymer structure may have been better protected against 
the hydrolysis, since the shorter chains can organise better and form crystallites more easily than 
the longer chains of HMW. The lactide content in HMW P(CL/LA) was slightly higher than in 
LMW P(CL/LA), which partly accounts for the faster hydrolysis rate. Based on the results in 
Publications I and II, it is feasible to formulate a device for further testing which is designed for 
long-term treatment of breast cancer after surgery. 
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3.2 Controlled release from poly(ε-caprolactone-co-DL-lactide) 
 
The applicability of the P(CL/DL-LA) copolymers for matrix type controlled release devices was 
further studied in Publications III and IV. The aim of these studies was to investigate how the 
release rate from the copolymers can be modified by changing the copolymer composition, 
hydrophilicity of the copolymer and the amount of model compound in the device. In addition to 
Publications I and II, a more detailed characterization of the interactions between model drugs and 
copolymers was performed. Hydrolytic degradation of the copolymers was recorded, and thus the 
comparison between degradation and release profiles was obtained. The hydrophilicity of the 
copolymer matrix was altered using PEG co-initiators, since they have been found to increase the 
degradation rate and the hydrophilicity of the lactone polymers (Cohn and Younes, 1988, 
Kricheldorf and Meier-Haack, 1993, Huang et al., 1997). The release of two model compounds, 
theophylline and propranolol hydrochloride, at different loadings (2-30 wt.%) was studied in 
Publication III, where the solubility of the model compounds was evaluated with DSC 
measurements. DL-lactide, instead of L-lactide, was again used as a comonomer, since amorphous 
polymers were preferred in the preparation of controlled release devices. In Publication IV, the 
release of theophylline, propranolol hydrochloride and lidocaine (10 wt.%), from copolymer with 
high lactide comonomer content was studied. It was of interest to see if the different model 
compounds would diffuse faster through the matrix compared to toremifene citrate studies and to 
compare the effects of hydrolytic degradation and release rates. Molecular modelling based on the 
molecular mechanics and dynamics simulations was performed in order to study the interactions 
between the theophylline model compound and homo- and copolymers of lactide and ε-
caprolactone units. In the sample codes, the number after the code for theophylline (T), 
propranolol hydrochloride (P), or lidocaine (L) indicates the amount of model compound in the 
device as percentage weight. 
 
 
3.2.1 Modification of copolymers by using PEG as a co-initiator 
 
The properties of the different polymers used in studies III and IV are listed in Table 2. Total 
monomer conversion was nearly complete in the bulk polymerisation, since no monomer peaks 
could be observed in 1H-NMR spectra. The hydrophilicity of the copolymers as well as the level 
of average molecular weight was modified using different co-initiators i.e. glycerol and 
polyethylene glycols. Contact angle measurements were carried out in order to establish 
differences in the hydrophilicity of the copolymers and lower contact angles were observed for 
polymers containing PEG. Caprolactone (10 wt.%) was introduced as a comonomer in P(DL-LA) 
in order to lower the glass transition temperature of amorphous homopolymer, which is around 
55°C. As the temperature is lowered and approaches the glass transition temperature, the rate of 
diffusion decreases, reflecting a diminishing molecular motion (Plazek and Ngai, 1996). 
Copolymerisation lowered the glass transition temperature below body temperature to 30°C, and 
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this was expected to enhance the diffusion of the model compounds in the matrix. P(CL10/LA90) 
containing 90 wt.% of DL-lactide in the feed was amorphous and very hydrophilic due to the high 
lactide content. The molecular weight was moderate, which should also have enhanced diffusion 
compared to the high molecular weight polymer. The elastomeric copolymer matrix, 
P(CL60/LA40), was polymerised using 40 wt.% of DL-lactide in the feed. 
 
Table 2.  Characteristics of the (ε-caprolactone/DL-lactide) copolymers (Data from III and IV). 
 
13C NMR SEC DSC Polymer code 
 
Co-initiator 
and 
content 
Monomer 
composition 
in feed 
CL/DL-LA 
!n !w MWD Tg Tm 
(wt.%/wt.%) (mol%) (mol%) 
Average 
caproyl 
sequence 
length 
Average 
lactidyl 
sequence 
length (g mol-1) (g mol-1)  (°C) (°C) 
P(CL95/LA5) Glycerol 0.3 96/4 19.7 1.6 81 400 146 000 1.8 -59 52 
P(CL/PEG4/LA) PEG4000 0.1 96/4 17.3 1.9 67 800 155 000 2.3 -55 55 
P(CL/PEG1/LA) PEG1000 0.5 96/4 17.5 1.7 45 300 79 500 1.8 -55 52 
P(CL60/LA40) Glycerol 0.05 65/35 3.4 3.0 150 000 280 000 1.9 -31 - 
P(CL10/LA90) Glycerol 0.5 12/88 -a) 21.6 43 300 60 300 1.4 30 - 
a) Not determined 
 
  
3.2.2 Interactions of the model compounds with the copolymers 
 
The solubility of the model compound into the polymer matrix affects the rate of release and thus 
it was of interest to estimate whether the model compounds were dissolved or dispersed into the 
polymer matrices. The release rate from dissolved monolithic systems is faster than the release 
rate from dispersed monolithic devices, i.e., according to Higuchi (1961), the higher the solubility 
the greater the release rate of the model compound. 
 
Solubility of model compounds in P(CL/DL-LA) with minor lactide content 
 
Introduction of the hydrophilic polyethylene glycol block did not alter the glass transition 
temperature of the modified copolymers (Table 3). The presence of model compounds, 
theophylline or propranolol hydrochloride, did not alter the Tg of copolymers either, and thus they 
are assumed to have low solubility in the copolymers. The changes in crystallinity of the samples 
were evaluated by comparing enthalpy of fusion values, which were calculated in theoretical 
proportions from DSC curves. The presence of small molecular weight compounds did not affect 
the crystallinity of the copolymers, except in P(CL95/LA5) T5, where the enthalpy increased by 
9%. Flexible polyethylene glycol blocks in the copolymer backbone hinder the alignment of long 
macromolecular chains i.e. slightly lower crystallinity was observed in PEG modified copolymers. 
 26 
In dispersed devices, the drug concentration exceeds the saturation solubility of drug in the 
polymer and discrete drug particles exist within the matrix. In such cases, the melting peak of the 
model compound can be determined by DSC. In order to study the solubility of theophylline (Tm 
274.6°C) in the copolymer, the DSC was heated once up to 320°C. No theophylline peaks were 
seen in P(CL95/LA5) T2 and P(CL95/LA5) T5 samples. Melting of the theophylline crystals 
around 220°C was observed in all of the samples with higher loadings. The tendency of 
theophylline to exist in crystal form in a variety of samples suggests that it has a limited solubility 
in the copolymers used. The measured enthalpy values indicate that theophylline was soluble in 
copolymers when less than 10 wt.% was added, and was partly dispersed at higher loadings.  
 
Table 3. Glass transition temperatures, melting temperatures and heat of fusion of P(CL/DL-LA) 
copolymers and theophylline model compound determined by DSC (Data from III). 
 
Sample Polymer  Model Compound 
 Tg 
(°C) 
Tm 
(°C)  
 ∆H 
(J/g) 
  
 (wt.%) 
∆H 
(J/g) 
Theophylline - - -  100 117 
P(CL95/LA5) -56 52 66  0 - 
P(CL95/LA5) T2 -55 52 64  2 -a) 
P(CL95/LA5) T5 -55 53 72  5 -a) 
P(CL95/LA5) T10 -55 54 63  10 70 
P(CL95/LA5) T15 -56 53 64  15 120 
P(CL95/LA5) T30 -55 54 62  30 117 
P(CL/PEG1/LA) -55 52 62  0 - 
P(CL/PEG1/LA) T10 -55 53 53  10 50 
P(CL/PEG4/LA) -55 55 59  0 - 
P(CL/PEG4/LA) T10 -54 56 60  10 60 
a) no peak detected 
 
All the samples containing propranolol hydrochloride showed a melting peak around 
160°C (propranolol hydrochloride melts at 164.9°C), except P(CL95/LA5) P2. This indicates that 
only small amount of propranolol hydrochloride was dissolved in the matrix and the rest was 
dispersed. Propranolol hydrochloride had a lower solubility in P(CL/LA) copolymers compared to 
theophylline, since a larger portion of loaded propranolol chloride was found to exist in the crystal 
form. 
 
Solubility of model compounds in amorphous copolymers 
 
Of the three model compounds added to P(CL10/LA90), only lidocaine affected the glass 
transition temperature of the copolymer by shifting it down significantly, and thus acting as a 
plasticizer in the matrix. This, together with the fact that the polymer device remained transparent 
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after the introduction of lidocaine, indicates that it was dissolved in the matrix (10 wt.%). 
Scanning electron micrographs of the fracture surfaces of the copolymer with lidocaine and 
theophylline are shown in Figure 10. 
 
Figure 10. SEM micrographs of the P(CL10/LA90) copolymer containing 10 wt.% of a) lidocaine 
and b) theophylline (IV). 
 
SEM micrographs revealed clear differences in the morphologies of the copolymer samples 
containing 10 wt.% of different model compounds. The morphology of the copolymer containing 
lidocaine appears smooth and no particles can be observed. On the other hand, the morphology of 
the samples containing theophylline or propranolol hydrochloride was rougher. A transparent 
device was also obtained when 10 wt.% theophylline was mixed in the P(CL60/LA40) matrix, 
although no significant change in the glass transition temperature was observed. 
 
 
3.2.3 Estimating interactions by molecular modelling  
 
In the Flexiblend method, the energy of mixing is estimated by calculating the interaction energies 
between short polymer chain segments (A) and a model molecule (B), as well as between like 
pairs A-A and B-B. The energy of mixing ∆E is then calculated:  
  
A negative result indicates that the compounds are miscible, i.e., the overall interactions between 
A and B are strong enough to provide miscibility. The more negative the result, the more likely it 
is that miscibility occurs.  
 Due to the local nature of interactions, only short chain segments need to be treated in the 
Flexiblend approach. For the calculations, three chain segments of approximately the same length 
were constructed: a chain of lactic acid units with five ester groups (PLA), a segment having a 
lactide unit (two lactic acid groups) between caprolactone units (P(CL-LA-CL)), and a chain 
)(
2
1)AB( BBAAAB EEEE +−=∆
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consisting of three ε-caprolactone units (PCL). In all cases, the segments ended with alkyl groups 
to avoid artificial effects due to the chain ends.  
 According to the AM1 calculations performed on theophylline, the molecule is almost 
planar. Additionally, theophylline is highly polar, the dipole moment being 6.5 D. The results 
from the Flexiblend calculations are presented in Table 4, which shows that for all polymer chain 
segments the mixing energies, and thus the interactions with theophylline, are small. Importantly, 
however, the calculations clearly show that increasing interaction between theophylline and the 
polymer matrix is obtained as the amount of lactide units increases.  
 
Table 4.  Results of the Flexiblend calculations (Data from IV). 
 
Chain segment ∆Etot  (kcal mol-1) 
PLA -0.9 + 0.4 
P(CL-LA-CL) 0.5 + 0.4 
PCL 0.7 + 0.4 
 
 
 Figure 11 presents an optimised pair of theophylline and chain segment representing PLA 
obtained from the Flexiblend calculations. A detailed inspection shows that theophylline resides 
in a pocket held together by interactions between carbonyl oxygens in the ester groups of the 
polymer and carbonyl carbon in theophylline. Furthermore, carbonyl carbon in PLA interacts with 
the oxygen atom in the theophylline carbonyl group. These distances are all in the range of 2.9-3.1 
Å. The planarity of theophylline enhances the possibility for simultaneous interactions from 
several directions, which makes the total effect of the interactions stronger.  
 
Figure 11.  An example of an optimised pair of theophylline and PLA chain segment showing 
interactions between the functional groups in the molecules (IV). 
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3.2.4 Effect of comonomer ratio and hydrophilicity of the copolymer on the release profile  
 
Cumulative release profiles of theophylline and propranolol hydrochloride (10 wt.%) from 
P(CL95/LA5) and PEG modified copolymers are shown Figure 12. The release profiles of 
different copolymer samples containing theophylline were similar. The initial release is fast from 
all copolymers. After approximately 30% is released, the release rate decreases and the 
differences between the copolymer matrices become evident. Faster theophylline release rates 
were obtained when the hydrophilicity of the copolymer was increased. An even greater effect on 
the release rate of propranolol hydrochloride was observed from PEG modification where the 
release flux of the hydrophilic drug was more than doubled from the modified matrix. The 
addition of hydrophilic polyethylene glycol blocks into the backbone of the chain increased water 
absorption and the degradation was faster when PEG 4000 was used as a co-initiator. 
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Figure 12. The cumulative release of theophylline (open symbols) and propranolol hydrochloride 
(closed symbols) from copolymers with different hydrophilicity. P(CL95/LA5) T10 (□), 
P(CL95/LA5) P10 (■), P(CL/PEG1/LA) T10 (∆), P(CL/PEG1/LA) P10 (▲), 
P(CL/PEG4/LA) T10 (○). Results are averages (n=3) with standard error bars, (Data from 
III). 
 
 
The addition of theophylline and propranolol hydrochloride at different loadings did not 
have an effect on the glass transition temperatures or melting temperatures of the P(CL95/LA5) 
copolymers, which indicates low interaction between the macromolecular chain and the model 
compounds. The solubility of the model compounds in the matrices was confirmed to be low by 
DSC measurements, where melting of the dispersed particles could be observed in most samples. 
Theophylline was soluble in copolymers when less than 10 wt.% was added and was partly 
dispersed at higher loadings. The difference in the release rate profiles was also evident when 
samples containing different amounts of theophylline, below and above the solubility limit, were 
compared. The release was initially faster from the samples where the model compounds were 
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molecularly dissolved (Figure 13). The release of both model compounds followed square root of 
time kinetics in dispersed devices. 
 
Figure 13. The effect of loading on the release rate of theophylline (a) and propranolol chloride (b) 
from P(CL95/LA5) copolymer. Drug load 2 wt.% (◊), 5 wt.% (□), 10 wt.% (∆), 15 wt.% 
(○), and 30 wt.% (x). Results are averages (n=3) with standard error bars, (Data from III). 
 
 
 The release of three different model compounds from P(CL10/LA90) copolymer matrix as 
well as the change in the molecular weights of the copolymers is presented in Figure 14. In each 
case, release is ultimately governed by the matrix degradation. Diffusion controlled release is 
slow, and rapid release of the model compounds only occurs following a significant loss of 
molecular weight, after about 40 days of hydrolysis. At this time, the molecular weight of the 
copolymer was significantly reduced, the devices lost their shape, and a clear burst on the release 
profile was observed. There is a slight delay in the burst of propranolol hydrochloride but, in all 
cases, less than 20% of the release of the model compounds was diffusion controlled. The 
solubility of the model compound in the matrix material did not affect the release rate observed. 
Lidocaine was dissolved in the copolymer, but the release was nonetheless governed by the 
degradation of the matrix. The molecular modelling showed increasing interaction between 
theophylline and the polymer matrix as the amount of lactide units increased. This may partly 
explain the slow diffusion rate observed in the high lactide content copolymer matrix 
P(CL10/LA90). 
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Figure 14.  Cumulative release profiles of model compounds (10 wt.%, open symbols) from 
P(CL10/LA90) copolymer devices and their relative loss of molecular weight; (●) 
propranolol hydrochloride device, (■) lidocaine device, and (▲) theophylline device (IV). 
 
 
The rate of degradation measured by the change in average molecular weight was not 
significantly affected by the presence of model compounds in any of the copolymers, which was 
rather surprising since there was a difference in the amounts of water absorbed. Water absorption 
over one month is 31% for theophylline, 55% for lidocaine, and 80% for propranolol 
hydrochloride containing P(CL10/LA90) devices, while the copolymer alone absorbs 30% water 
in 28 days. No vital change in the mass of the copolymers (besides model compound loss from 
devices) was observed in 28 days, although all devices lost their shape by that time and therefore 
water absorption and mass loss were not determined further.  
Figure 15 shows the effect of the comonomer ratio on the release rates of theophylline. 
Constant, nearly zero order, release of theophylline was obtained with P(CL60/LA40) copolymer. 
Apparently, the amorphous nature of the copolymer together with caprolactone blocks enhanced 
the rate of the release compared with the copolymer of higher lactide content and semi-crystalline 
P(CL95/LA5) copolymer. Also, the higher solubility of theophylline compared to P(CL10/LA90) 
promoted the release. Due to its low Tg and lack of crystalline structure, the P(CL60/LA40) 
copolymer did not retain its form well at 37°C. Nevertheless, the copolymer provided a very 
steady rate of release and concurrent degradation of the device would enable repeated 
administration with a new device if required. The copolymer lost nearly 90% of its weight average 
molecular weight over the two months hydrolysis. The results clearly demonstrate that the desired 
release rates of these model compounds can be tailored by varying the compound loading, by 
modifying the hydrophilicity of the matrix copolymer from matrices with low lactide content and 
by choosing the appropriate comonomer ratio between ε-caprolactone and DL-lactide. 
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Figure 15. Release of 10 wt.% theophylline from P(CL/DL-LA) copolymers. Results are averages 
(n=3) with standard error bars, (Data from III and IV). 
 
 
3.3 Bioresorbable composites for bone replacement 
 
Composites of biodegradable polymers and bioactive glasses or glass-ceramics have been studied 
for a variety of applications in medicine. These include filling of bone defects (Higashi et al., 
1986, Ural et al., 2000), guided tissue regeneration (Kellomäki et al., 2000), fracture fixation 
(Shikinami and Okuno, 1999, Rokkanen et al., 2000), tissue engineering (Hutmacher, 2000) and 
drug delivery as discussed here previously. Bioabsorbable devices are designed to maintain 
fixation during healing, then decompose gradually, transferring stress to the healing tissues. In this 
study, two different composite materials for bone replacement have been developed and their 
properties in vitro have been evaluated. The first material combined the well known 
characteristics of the P(CL/DL-LA) copolymer with bioactive glass S53P4 (Publication V) and 
the second was a composite consisting of amorphous lactic acid based PEU-BDI and bioceramic 
filler, HA or BCP (Publication VI).  
 
 
3.3.1 Composite material of P(CL/LA) and bioactive glass S53P4 for use as a bone filler 
 
The aim was to produce a composite material with combined beneficial properties for applications 
in orthopaedics and in oral and maxillofacial surgery. Lack of in situ mouldability, and the 
relative brittleness of bioactive glasses and glass ceramics limit the range of applications. 
Bioactive glasses and glass ceramics react both in vivo in body fluids and in several solutions in 
vitro. Due to ion dissolution, a silica gel layer is formed on the glass surface in the first hours, 
depending on the reactivity of the bioactive glass. This is followed by Ca-P precipitation and 
crystallisation resulting in a hydroxy apatite layer covering the surface. Silica gel formed on glass 
granules is considered to offer favourable nucleation sites for apatite formation (Ohtsuki et al., 
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1992). Ideally, a composite material could combine the osteoconductive properties of bioactive 
glass with the processability of polymer to overcome limitations in the applicability of glass. 
Bioactive glass, S53P4, has shown good clinical performance in areas of compromised bone 
healing e.g. in the treatment of facial bone defects (Suominen and Kinnunen, 1996), obliteration 
of frontal sinuses (Peltola et al., 1998) and maxillary sinus augmentation (Turunen et al., 2002). A 
mouldable copolymer matrix enables the application and retention of the bioactive element at the 
operation site. The thermal properties of the P(CL/LA) copolymer can be adjusted to enable 
application by injection and moulding of the composite at relatively modest temperatures. 
Bioactive glass granules within the composite should be able to react and form an apatite layer on 
the composite surface, when exposed to body fluids. The biodegradation of the copolymer should 
also take place, enhancing the dissolution of bioactive glass granules and ultimately leading to 
bonding with the target tissue.  
Different amounts of bioactive glass were incorporated in the P(CL95/DL-LA5) 
copolymer matrix in order to obtain slower (40 wt.%, equivalent to 23 vol.% glass) or accelerated 
bioactivity (60 or 70 wt.%, equivalent to 40 and 50 vol.% glass), i.e., slower or faster formation of 
a silica gel layer on the surface of the composite in dissolution. Two different granule size ranges 
of the bioactive glass were used, referred to as smaller (<45 µm) and larger (90-315 µm) range 
(Table 5). As the aim was to produce an injectable composite material, the molecular weight had 
to be such that the melt viscosity of the copolymer combined with the bioactive glass would not 
be too high. Use of the co-initiator (glycerol) allowed the molecular weight of the copolymer to be 
adjusted to the right level, i.e. weight average molecular weight of the copolymer was 110 000 g 
mol-1. By choosing the right comonomer ratio of ε-caprolactone and DL-lactide, the melting 
temperature of the copolymer was lowered to 50°C. 
 
Table 5. Composition of the bioactive composites consisting of P(CL/DL-LA) and bioactive glass 
used in study V. 
 
Composite Bioactive glass 
 granule size range in feed measured 
 (µm) (vol.%) (wt.%) (wt.%) 
P(CL/DL-LA) - - - - 
BG40S <45 23 40 39.0±0.8 
BG60S <45 40 60 58.7±1.0 
BG40L 90-315 23 40 39.9±0.3 
BG60L 90-315 40 60 60.8±1.3 
BG70L 90-315 50 70 71.0±1.9 
 
The presence of filler changes the mechanical properties of the polymeric materials. 
Hardness and stiffness are usually increased, while impact and tensile strengths decrease. Filler, 
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which does not have strong interactions with the matrix material, increases the storage modulus 
both above and below the glass transition, but will not alter the position of the glass transition on 
the temperature axis (Gradin et al., 1989). Bioactive glass does not interact with the P(CL/DL-
LA) copolymer matrix, since the glass transition is not affected. The damping peak in DMTA 
measurements decreases with increasing glass content. Lowering of the damping energy suggests 
the restraining effect of the filler on the polymer segment mobility, demonstrating the increasing 
trend in composite rigidity.  
The neat copolymer was fairly stable over six months hydrolysis due to the hydrophobic 
nature of the polycaprolactone blocks. Water absorption into the neat copolymer was less than one 
percent in the 168 days of hydrolysis. The presence of bioactive glass increased the water 
absorption, and the higher area/volume ratio of the smaller granule size range clearly enhanced 
the water absorption, up to 16%, compared to larger granules in the matrix even at 70 wt.% load. 
In composite materials, the fluid molecules diffuse into both matrix and filler phase. In this case, 
the majority of the diffusion occurs through the interface of the bioactive glass and the 
biodegradable polymer, since the polymer is relatively hydrophobic. The fluid diffuses through 
the interface by capillarity and microcrack transport mechanisms. In turn, the increased water 
uptake clearly had an effect on the rate of ester hydrolysis, since the average molecular weights of 
the composite samples were observed to decrease much faster. As random chain scission proceeds 
in the copolymer, smaller chain fragments are formed. The change in average chain length can be 
observed as an increasing difference between the number average and weight average molecular 
weight. Figure 16 shows the relative decrease of the average molecular weights for the polymer 
matrix and the composite containing 60 wt.% of bioactive glass of smaller range. The rate of 
chain scission is accelerated by the presence of the bioactive glass. 
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Figure 16.  Changes in average molecular weights of P(CL/DL-LA) copolymer (+) and composite 
BG60S (▲) containing 60 wt.% of smaller range bioactive glass during hydrolysis in SBF 
at 37°C (Data from V). 
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Formation of Ca-P deposition on the surface of the composites after dissolution in SBF at 
37°C was recorded by SEM. The degradation rate of the copolymer matrix has a detrimental 
effect on the bioactivity of the proposed injectable composite material. As formed, all the 
bioactive glass granules are intimately imbedded in the polymer matrix and even the near surface 
granules are covered by a polymer film of at least 1 µm thickness. Only the exposure of these 
granules, subsequent ion dissolution and formation of the Ca-P layer on the surface of the 
composite would enable bonding to soft tissue as well as hard tissue. Whereas the degradation rate 
of the P(CL/DL-LA) copolymer would not be fast enough to expose these granules, the 
combination of high glass content, increased water absorption and hence a faster degradation rate, 
provided enough enhancement so that differences in the surface properties of the different 
composites were evident after one week of hydrolysis. Higher water absorption and faster loss of 
molecular weight were observed in the composites containing the smaller granule size range of 
bioactive glass, namely <45 µm.  
The first signs of Ca-P precipitation were observed on the composite containing 60 wt.% 
of the smaller glass after 24 hours of dissolution in SBF at 37°C, and within one week some 
deposition was observed on all of the composite materials. No surface precipitation was observed 
on the unfilled polymer sample. The fast deposition of Ca-P on the composite surface indicated 
fast ion dissolution and was probably due to the closer packing of the smaller bioactive glass 
granules with a higher surface/volume ratio in the matrix. Smaller granules could also pack better 
near the surface of the composite than larger granules with a lower surface/volume ratio. Ca-P 
crystals formed on the surface of the composite containing 60 wt.% of <45 µm glass after 3 weeks 
hydrolysis are shown in the SEM micrograph in Figure 17. 
 
 
Figure 17.  Formation of Ca-P deposition on the surface of the composite BG60S containing 60 wt.% 
of smaller bioactive glass after three weeks dissolution in SBF at 37°C (magnification x 
5000) (V). 
 
It was shown that a homogeneous distribution of the bioactive glass granules in the 
composites was obtained after compounding and compression moulding. Such uniform 
distribution is important in order to achieve the appropriate mechanical and biological 
performance of bioactive biodegradable composites. The formation of a biologically active Ca-P 
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layer on the surfaces of the composites in hydrolysis indicates in vitro bioactivity and it was found 
to be dependent on the weight fraction and granule size range of the bioactive glass used. The 
thermal properties of the polymer matrix would also enable the in situ application of the material. 
The presence of the bioactive glass affected the rate of the polymer degradation. The greater the 
amount and the smaller the granule size of the bioactive glass present, the more rapid was the 
deterioration in molecular weight of the samples. This can be attributed to the high water 
absorption in the composites accelerating the ester hydrolysis of the copolymer matrix. The 
correlation of in vitro and in vivo bioactivity of the composites needs to be established, but based 
on the in vitro evaluation, these composites have the potential for a variety of applications as 
implant materials in orthopaedics and dentistry. 
 
 
3.3.2 Amorphous bone replacement material consisting of bioceramics and poly(ester-
urethane) 
 
As a matrix polymer, poly(lactic acids), are well known bioabsorbable and biocompatible 
polyesters, which are increasingly used as biomaterials for sutures, degradable films and fracture 
fixation. Here, an alternative route to obtain high molecular weight lactic acid based polymer was 
applied to obtain amorphous polymer matrix for bioactive fillers. This two-step synthesis route 
would enable further tailoring of the matrix, for example by varying the length of the prepolymer 
chains or comonomers. In this study, composites were prepared successfully by melt blending 
particulate bioceramic fillers, HA and BCP, at high, i.e. 20 and 40 vol.% loads (corresponding to 
40 and 64 wt.%), with purified, thermoplastic lactic acid based PEU-BDI (Mw 175 000 g mol-1). 
The aim was to develop a material that could withstand sterilization and retain the mechanical 
properties long enough for the healing to proceed. The effects of the γ-sterilization as well as the 
DMA properties in hydrolysis were characterized. DMA is useful to evaluate the viscoelastic 
properties of a polymer. The viscoelastic response is the direct reflection of the polymer structure, 
so it is commonly used to study the structure of a polymer and the interaction between the 
constituents of polymer composites. 
The reinforcing effect of the fillers and filler content on the dynamic mechanical 
properties of the composites was clear, as shown in Figure 18. The stiffness of the materials, i.e. 
storage modulus values, increased with increasing filler content within the whole range of testing 
temperature, as is expected with the addition of rigid fillers. Tg values also increased (Table 6) as 
the filler content increased, indicating strong interactions between the filler and matrix. Widening 
of the glass transition region is due to the polymer becoming adsorbed onto the filler. Adsorption 
of polymer onto a surface restricts molecular motion, changes the density of packing of polymer 
chains and modifies the conformation and orientation of chain segments in the neighbourhood of 
the surface (Nielsen and Landel, 1994). Also strong secondary interactions between the ceramic 
fillers and poly(ester-urethane) can increase the Tg. The SEM micrographs of the cryogenic 
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fracture surfaces confirmed the strong interfacial bonding since no particle pullout was observed. 
Modulus values of the composites were within the ranges reported for cortical bone, 7-25 GPa. 
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Figure 18. Storage modulus values of the composites and unfilled PEU-BDI before and after 
sterilization (VI). 
 
 
The type of calcium phosphate filler did not affect the morphology of the composite; in all 
cases the fillers were homogeneously dispersed and in close contact with the polymer matrix. 
Average molecular weights and Tg values, determined from the peak of the loss modulus values, 
before and after γ-irradiation are shown in Table 6.  
 
Table 6.  Effects of gamma irradiation on molecular weights and glass transition temperatures of 
PEU-BDI and its composites. DMTA measurements are averages of five with standard 
errors shown (VI). 
After processing After radiation 
SEC DMTA SEC DMTA 
Sample 
!w 
(g mol-1) 
MWD Tg 
(°C) 
!w 
(g mol-1) 
MWD Tg 
(°C) 
PEU-BDI 170 000 2.3 54.2±0.2 102 000 2.2 53.5±0.2 
PEU20HA 148 000 2.1 56.4±0.2 99 700 2.1 55.8±0.2 
PEU40HA 123 000 2.2 57.6±0.5 86 500 2.1 56.4±0.6 
PEU20BCP 153 000 2.4 56.3±0.3 99 300 2.2 55.0±0.5 
PEU40BCP 137 000 2.4 57.3±0.2 99 300 2.2 57.3±0.2 
 
The two major effects of radiation on a polymer are: chain scission occurring as a random 
rupturing of bonds, which reduces the molecular weight and the viscosity of the polymer, and 
cross-linking, which results ultimately in the formation of three-dimensional networks. Usually, 
both mechanisms occur simultaneously (Sintzel et al., 1997). Composites were sterilized by a 
standard commercial γ-irradiation method using a nominal dose of 2.9 Mrad. Some random 
rupture of the polymer chains occurred, since the average molecular weights decreased by 30-
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35%, as shown in Table 6. It is noteworthy that after sterilization all average molecular weights 
were similar, even though there were differences after processing. It seems that the polymer 
exhibits a threshold value of the molecular weight around 100 000 g mol-1. This could be due to 
difference in the susceptibility of the different connecting groups in the polymer towards 
irradiation and thermal effects (Tuominen et al., 2002). Higher doses of irradiation or more severe 
processing conditions would probably cause further destruction of polymer chains. Although 
some loss of molecular weight was observed, mechanical properties remained unchanged by 
irradiation and storage modulus values were similar to those before sterilization (Figure 18). 
The hydrolysis of bulk degrading bioresorbable polymers usually proceeds by losing 
molecular weight at first, followed by loss of mass in the second stage when molecular weight has 
decreased to 15 000 g mol-1 or less (Pitt et al., 1981b). In the hydrolysis of PEU-BDI and its 
composites, average molecular weights did not change much over five weeks, which was 
somewhat unexpected (Figure 19). When similar, but not purified poly(ester-urethane), which had 
been linked with 1,6-hexamethylene diisocyanate, was hydrolyzed at 37°C, the weight average 
molecular weight dropped by half during five weeks hydrolysis (Hiltunen et al., 1998). In that 
case the water absorption was higher, at approximately 20%, but again no mass loss was 
observed. PEU-BDI is biodegradable, but the rate of degradation is significantly slower than is 
usually observed in amorphous poly(lactic acids). The biodegradation of PEU-BDI is clearly 
affected by the purification procedure, which is also known to affect the stability of PLAs (Hyon 
et al., 1998). Solvent precipitation removes monomers or other short chains (e.g. dimer, lactide) as 
well as catalyst residuals, all of which can enhance the degradation rate in hydrolysis.  
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Figure 19. Water absorption and loss of molecular weight over five weeks of hydrolysis at 37°C; 
PEU-BDI (x), PEU20HA (●), PEU40HA (○), PEU20BCP (■), and PEU40BCP (□) (VI). 
 
 
The amount or the type of filler did not influence the water absorption into the composite 
materials to a degree that would have affected the degradation of the polymer matrix (Figure 19). 
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The hydrolytic degradation of PEU-BDI was neither accelerated nor retarded by the presence of 
the fillers over the five weeks of hydrolysis. No mass loss was observed, since the degraded 
chains still remained long and showed no water solubility. Even though no major degradation 
occurred over 5 weeks, the dynamic mechanical analysis showed a decrease in the mechanical 
integrity of the composites during that time. The DMTA data showed different decreases in 
modulus values for the composites and PEU-BDI after immersion in saline. PEU-BDI retained its 
modulus well, whereas a faster loss of stiffness was observed in all the composite materials. This 
difference is attributed to the higher water absorption observed in the composites where the 
absorbed fluid concentrates at and disrupts the interface between the fillers and PEU-BDI matrix, 
easing deformation of the materials.  
Relative modulus values, where the storage modulus of the composite is divided by the 
storage modulus of the unfilled polymer at the same temperature, were calculated at 37°C and are 
shown over the five-week hydrolysis period in Figure 20. Relative modulus values showed faster 
loss of rigidity at high filler content for HA containing samples than for BCP containing samples. 
The storage modulus values of all the composite materials remained within ranges that are 
mechanically compatible with bone over the whole five weeks of hydrolysis. Initially, the 
dynamic mechanical properties of the composites depended on the filler content and only minor 
differences between the composites containing either HA or biphasic calcium phosphate were 
observed. However, a faster loss of stiffness was observed in PEU40HA composites compared 
with PEU40BCP composite over the five-week in vitro hydrolysis. Relative modulus values are 
close for both fillers initially, but PEU40HA composites lose their stiffness faster than 
PEU40BCP composites. In general, the stiffness of the composite materials containing 40 vol.% 
ceramic filler reduced faster. The reinforcing effect of the fillers in the composite materials was 
retained over the hydrolysis time, since the relative modulus values remained above 1.0. It can be 
concluded that these materials have potential for application as fracture fixation materials. 
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Figure 20.  Change in the relative modulus of the composites PEU40BCP (■), PEU40HA (●), 
PEU20BCP (□) and PEU20HA (○) at 37°C over five weeks of hydrolysis (VI). 
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4 CONCLUSIONS 
 
 
The bioresorbable polymers studied here were mainly synthesized by ring-opening polymerisation 
of ε-caprolactone and DL-lactide, but also by polycondensation of lactic acid followed by chain 
linking with BDI. The aim was to develop and on the other hand characterize polymer and 
composite materials that would be applicable as biomaterials and answer sufficiently the 
requirements for such materials from an engineering viewpoint. Polymers were tailored and 
characterized in vitro for different biomedical applications, aiming ultimately for controlled drug 
delivery or bone replacement devices. The following conclusions can be drawn from the studies 
presented in this thesis and in Publications I-VI: 
 
●  A biodegradable device for the controlled release of toremifene citrate was developed. The 
release period could be adjusted from 3 months to 1 year by varying the initial molecular 
weight of the poly(ε-caprolactone-co-DL-lactide), by incorporating toremifene citrate in 
silica xerogel in the composite device or by changing the dimensions of the device. 
 
●  The hydrophilicity of the poly(ε-caprolactone-co-DL-lactide) with minor lactide content 
was modified using different co-initiators, i.e. glycerol and poly(ethylene glycols). 
Increasing the hydrophilicity of the matrix also increased the release rates of model 
compounds used. The release of model compounds, theophylline and propranolol 
hydrochloride, followed square root of time kinetics in dispersed devices. Matrix devices 
consisting mostly of lactide were not found to be optimal for controlled release, since less 
than 20% of the release of the model compounds was diffusion controlled. Diffusion 
controlled release was slow, and the model compounds were only released rapidly 
following a significant loss of molecular weight. It was demonstrated that the desired 
release rates of the model compounds could be tailored by varying the compound loading, 
by modifying the hydrophilicity of the matrix copolymer and by choosing the appropriate 
comonomer ratio between ε-caprolactone and DL-lactide. 
 
● Composite material for filling bone defects and use in guided tissue regeneration was 
developed by combining poly(ε-caprolactone-co-DL-lactide) copolymer with bioactive 
glass S53P4. The properties of the copolymer were adjusted to enable application by 
injection and moulding of the composite in situ at relatively modest temperatures. The 
formation of a biologically active Ca-P layer on the surfaces of the composites in 
hydrolysis indicated in vitro bioactivity and was found to be dependent on the weight 
fraction and granule size range of the bioactive glass used. 
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●  A composite material consisting of amorphous lactic acid based poly(ester-urethane) 
reinforced with bioceramic fillers, HA or BCP, was developed for use as a bone 
replacement material. Melt blending and sterilization by gamma-irradiation caused some 
chemical degradation, but did not affect dynamic mechanical properties. The storage 
modulus values of all the composite materials remained within ranges that are 
mechanically compatible with bone over the whole five weeks of hydrolysis and are 
thought to have potential for application as fracture fixation materials. 
 
ε-Caprolactone/DL-lactide copolymers are known to be biocompatible and their wide range of 
properties provides a good basis for their use in controlled drug release devices. The properties of 
the polymer/drug devices are always dependent on the specific combination and should thus be 
tested for desired profile. It is acknowledged that the effects of the sterilization should have been 
included in the study of these materials in all publications and that the biological and medical 
properties are yet to be established for these materials. However, the biocompatibility of 
reinforced poly(ester-urethane) composites has been assessed using an in vitro human 
osteosarcoma (HOS) cell culture model (Rich et al., 2001). From the results of the cytotoxicity 
test, biochemical evaluation and morphological assessment, the polymer and composites were 
biocompatible with HOS cells and encouraged cell attachment and growth. Also, the evaluation of 
the biological behaviour of the bioactive glass composite materials has produced some promising 
results (Närhi et al., 2002) and further development of the material for orthopaedic and dental 
applications is in progress. 
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